Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer

Abstract Purpose To evaluate the safety, tolerability, and preliminary efficacy of multiple doses of pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients. Methods According to the “3 + 3” dose‐escalation principle, patients received intraven...

Full description

Saved in:
Bibliographic Details
Main Authors: Jieran Long, Xuefei Li, Lin Wu, Guohua Yu, Aimin Zang, Yanqiu Zhao, Jinsheng Shi, Ligong Nie, Xuan Zhao, Jian Fang
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
overall survival
safety
second‐line monotherapy
small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.70059
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items